Effects of anti-tumor necrosis factor therapy on body composition and insulin sensitivity in patients with psoriasis

Archives of Dermatology

Volumn 148, Issue 9, 2012, Pages 1089-1091

  Kofoed, Kristian ^a   Clemmensen, Anders ^a   Mikkelsen, Ulla R ^b,c,d   Simonsen, Lene ^b   Andersen, Ove ^b   Gniadecki, Robert ^a,d  

^a BISPEBJERG HOSPITAL   (Denmark)

^b Mental Health Services CPH   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; C PEPTIDE; CALCIPOTRIOL; ETRETIN; GLUCOSE; HEMOGLOBIN A1C; INFLIXIMAB; LEPTIN; METHOTREXATE; STEROID; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; ARTICLE; BODY COMPOSITION; BODY FAT; CLINICAL ARTICLE; DIET; DISEASE SEVERITY; DUAL ENERGY X RAY ABSORPTIOMETRY; EXERCISE TEST; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; HEMOGLOBIN BLOOD LEVEL; HORMONE BLOOD LEVEL; HUMAN; HYPERINSULINEMIC EUGLYCEMIC CLAMP; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; MALE; OXYGEN CONSUMPTION; PHOTOTHERAPY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PSORIASIS; QUESTIONNAIRE; SAMPLE SIZE; TREND STUDY; ULTRAVIOLET B RADIATION;

ADULT; BODY COMPOSITION; HUMANS; INSULIN RESISTANCE; MALE; MIDDLE AGED; PSORIASIS; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84866495415     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archdermatol.2012.1753     Document Type: Article

References (10)

1. Boehncke WH, Boehncke S, Schön MP. Managing comorbid disease in patients with psoriasis. BMJ. 2010;340:b5666.
2. Gustafson B, Hammarstedt A, Andersson CX, Smith U. Inflamed adipose tissue: a culprit underlying the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol. 2007;27(11):2276-2283.
3. Renzo LD, Saraceno R, Schipani C, et al. Prospective assessment of body weight and body composition changes in patients with psoriasis receiving anti-TNF-α treatment. Dermatol Ther. 2011;24(4):446-451.
4. Ryden M, Dicker A, van Harmelen V, et al. Mapping of early signaling events in tumor necrosis factor-alpha-mediated lipolysis in human fat cells. J Biol Chem. 2002;277(2):1085-1091.
5. Martínez-Abundis E, Reynoso-von Drateln C, Hernández- Salazar E, González-Ortiz M. Effect of etanercept on insulin secretion and insulin sensitivity in a randomized trial with psoriatic patients at risk for developing type 2 diabetes mellitus. Arch Dermatol Res. 2007;299(9):461-465.
6. Marra M, Campanati A, Testa R, et al. Effect of etanercept on insulin sensitivity in nine patients with psoriasis. Int J Immunopathol Pharmacol. 2007;20(4):731-736.
7. Solomon DH, Massarotti E, Garg R, Liu J, Canning C, Schneeweiss S. Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. JAMA. 2011;305(24):2525-2531.
8. La Cava A, Matarese G. The weight of leptin in immunity. Nat Rev Immunol. 2004;4(5):371-379.
9. Chen YJ, Wu CY, Shen JL, et al. Psoriasis independently associated with hyperleptinemia contributing to metabolic syndrome. Arch Dermatol. 2008;144(12):1571-1575.
10. Engvall IL, Tengstrand B, Brismar K, Hafström I. Infliximab therapy increases body fat mass in early rheumatoid arthritis independently of changes in disease activity and levels of leptin and adiponectin: a randomised study over 21 months. Arthritis Res Ther. 2010;12(5):R197.